

REFERENCES

- AlQassimi, S., AlBrashdi, S., Galadari, H., & Hashim, M. J. (2020). Global burden of psoriasis—comparison of regional and global epidemiology, 1990 to 2017. *International Journal of Dermatology*, 59(5), 566-571.
- Archier, E., Devaux, S., Castela, E., Gallini, A., Aubin, F., Le Maître, M., ... & Richard, M. A. (2012). Efficacy of Psoralen UV-A therapy vs. Narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review. *Journal of the European Academy of Dermatology and Venereology*, 26, 11-21.
- Augustin, M., Radtke, M. A., Glaeske, G., Reich, K., Christophers, E., Schaefer, I., & Jacobi, A. (2015). Epidemiology and comorbidity in children with psoriasis and atopic eczema. *Dermatology*, 231(1), 35-40.
- Bian, K. A., Harari, Y., Zhong, M., Lai, M., Castro, G., Weisbrodt, N., & Murad, F. (2001).
- Boehncke, W. H. (2015). Etiology and pathogenesis of psoriasis. *Rheumatic Disease Clinics*, 41(4), 665-675.
- Bolognia, J. L., Jorizzo, J. L., & Schaffer, J. V. (2012). *Dermatology e-book*. Elsevier Health Sciences.
- Bonandi, E., Christodoulou, M. S., Fumagalli, G., Perdicchia, D., Rastelli, G., & Passarella, D. (2017). The 1, 2, 3-triazole ring as a bioisostere in medicinal chemistry. *Drug Discovery Today*, 22(10), 1572-1581.
- Brahmachari, G. (Ed.). (2019). *Discovery and Development of Anti-inflammatory Agents from Natural Products*. Elsevier.
- Cai, L., Qin, X., Xu, Z., Song, Y., Jiang, H., Wu, Y., ... & Chen, J. (2019). Comparison of cytotoxicity evaluation of anticancer drugs between real-time cell analysis and CCK-8 method. *ACS omega*, 4(7), 12036-12042.
- Capon, F., Burden, A. D., Trembath, R. C., & Barker, J. N. (2012). Psoriasis and other complex trait dermatoses: from Loci to functional pathways. *Journal of investigative dermatology*, 132(3), 915-922.
- Chang, Z. Y., Chen, C. W., Tsai, M. J., Chen, C. C., Alshetaili, A., Hsiao, Y. T., & Fang, J. Y. (2023). The elucidation of structure–activity and structure-permeation relationships for the cutaneous delivery of phytosterols to attenuate psoriasiform inflammation. *International Immunopharmacology*, 119, 110202.
- Chanput, W., Mes, J. J., & Wichers, H. J. (2014). THP-1 cell line: an in vitro cell model for immune modulation approach. *International immunopharmacology*, 23(1), 37-45.
- Côté, B., Boulet, L., Brideau, C., Claveau, D., Ethier, D., Frenette, R., ... & Friesen, R. W. (2007). Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. *Bioorganic & medicinal chemistry letters*, 17(24), 6816-6820.
- Di Cesare, A., Di Meglio, P., & Nestle, F. O. (2009). The IL-23/Th17 axis in the immunopathogenesis of psoriasis. *Journal of Investigative Dermatology*, 129(6), 1339-1350.

- Di Meglio, P., Villanova, F., & Nestle, F. O. (2014). Psoriasis. Cold Spring Harbor perspectives in medicine, 4(8), a015354. <https://doi.org/10.1101/cshperspect.a015354>
- Down-regulation of inducible nitric-oxide synthase (NOS-2) during parasite-induced gut inflammation: a path to identify a selective NOS-2 inhibitor. *Molecular pharmacology*, 59(4), 939-947.
- Egeberg, A., Gisondi, P., Carrascosa, J. M., Warren, R. B., & Mrowietz, U. (2020). The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. *Journal of the European Academy of Dermatology and Venereology*, 34(8), 1695-1706.
- Feldman, S. R., & Krueger, G. (2005). Psoriasis assessment tools in clinical trials. *Annals of the rheumatic diseases*, 64(suppl 2), ii65-ii68.
- Flohr, C., & Hay, R. (2021). Putting the burden of skin diseases on the global map. *British Journal of Dermatology*, 184(2), 189-190.
- Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhali, M., & Klouz, A. (2012). Methotrexate side effects: review article. *J Drug Metab Toxicol*, 3(4), 1-5.
- Glickman, F. S. (1986). Lepra, psora, psoriasis. *Journal of the American Academy of Dermatology*, 14(5 Pt 1), 863-866.
- Gokhale, N. R., Belgaumkar, V. A., Pandit, D. P., Deshpande, S., & Damle, D. K. (2005). A study of serum nitric oxide levels in psoriasis. *Indian Journal of Dermatology, Venereology & Leprology*, 71(3).
- Griffiths, C. E. M., Christophers, E., Barker, J. N. W. N., Chalmers, R. J. G., Chimenti, S., Krueger, G. G., ... & Fry, L. (2007). A classification of psoriasis vulgaris according to phenotype. *British Journal of Dermatology*, 156(2), 258-262.
- Gudjonsson, J. E., Johnston, A., & Ellis, C. N. (2012). Novel systemic drugs under investigation for the treatment of psoriasis. *Journal of the American Academy of Dermatology*, 67(1), 139-147.
- Honma, M., & Nozaki, H. (2021). Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity. *Journal of clinical medicine*, 10(15), 3199. <https://doi.org/10.3390/jcm10153199>
- Hou, J., Liu, X., Shen, J., Zhao, G., & Wang, P. G. (2012). The impact of click chemistry in medicinal chemistry. *Expert opinion on drug discovery*, 7(6), 489-501.
- Ilmi, N., Ilyas, F., Adriani, A., & Djawad, K. (2023). A case report of HLA-Cw6 and phenotype discordances in monozygotic twins with psoriasis: The role of epigenetic mechanism. *Journal of Pakistan Association of Dermatologists*, 33(2), 791-795.
- International Organization for Standardization (ISO). (2012). ISO 10993-12: Biological Evaluation of Medical Devices: Sample Preparation and Reference Materials: Partie 12, Préparation Des Échantillons Et Matériaux de Référence. ISO.
- Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. (2010). Circulating Th17, Th22, and Th1 cells are increased in psoriasis. *Journal of Investigative Dermatology*, 130(5), 1373-1383.
- Kerdel, F., & Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. *Dermatologic therapy*, 28(6), 390-403.

- Lee, K. W., Lee, W. H., Han, B. S., Lee, J. H., Doo, E. K., & Kim, J. H. (2020). Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton's Tyrosine Kinase Inhibitor. *International Journal of Molecular Sciences*, 21(9), 3065.
- Liao, J., Zheng, H., Fei, Z., Lu, B., Zheng, H., Li, D., ... & Yi, Y. (2018). Tumor-targeting and pH-responsive nanoparticles from hyaluronic acid for the enhanced delivery of doxorubicin. *International journal of biological macromolecules*, 113, 737-747.
- Ling, T. C., Clayton, T. H., Crawley, J., Exton, L. S., Goulden, V., Ibbotson, S., ... & Mohd Mustapa, M. F. (2016). British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. *British Journal of Dermatology*, 174(1), 24-55.
- Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. *Journal of pharmacological and toxicological methods*, 44(1), 235-249.
- Liu, F. Z., Fang, H., Zhu, H. W., Wang, Q., Yang, Y., & Xu, W. F. (2008). Design, synthesis, and preliminary evaluation of 4-(6-(3-nitroguanidino) hexanamido) pyrrolidine derivatives as potential iNOS inhibitors. *Bioorganic & medicinal chemistry*, 16(1), 578-585.
- Lønnberg, A. S., Skov, L., Skytthe, A., Kyvik, K. O., Pedersen, O. B., & Thomsen, S. F. (2013). Heritability of psoriasis in a large twin sample. *British Journal of Dermatology*, 169(2), 412-416.
- Lønnberg, A. S., Skov, L., Skytthe, A., Kyvik, K. O., Pedersen, O. B., & Thomsen, S. F. (2016). Association of psoriasis with the risk for type 2 diabetes mellitus and obesity. *JAMA dermatology*, 152(7), 761-767.
- Maeda, A., Digifico, E., Andon, F. T., Mantovani, A., & Allavena, P. (2019). Poly (I: C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages. *European journal of immunology*, 49(5), 801-811.
- Marrakchi, S., Guigue, P., Renshaw, B. R., Puel, A., Pei, X. Y., Fraitag, S., ... & Smahi, A. (2011). Interleukin-36–receptor antagonist deficiency and generalized pustular psoriasis. *New England Journal of Medicine*, 365(7), 620-628.
- Meng, X. L., Yang, J. Y., Chen, G. L., Wang, L. H., Zhang, L. J., Wang, S., ... & Wu, C. F. (2008). Effects of resveratrol and its derivatives on lipopolysaccharide-induced microglial activation and their structure–activity relationships. *Chemico-biological interactions*, 174(1), 51-59.
- Menter, M. A., & Griffiths, C. E. (2015). Psoriasis: the future. *Dermatologic clinics*, 33(1), 161-166.
- Michalek, I. M., Loring, B., & John, S. M. (2016). Global report on psoriasis. World Health Organization.
- Morimura, S., Oka, T., Sugaya, M., & Sato, S. (2016). CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages. *Journal of Dermatological Science*, 82(3), 175-188.
- Muramatsu, S., Kubo, R., Nishida, E., & Morita, A. (2017). Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. *Modern rheumatology*, 27(1), 137-141.
- NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases. (2010). Psoriasis. [https://www.niams.nih.gov/health-topics/psoriasis#:~:text=Psoriasis%20is%20a%20chronic%20\(long,can%20be%20affected%20as%20well](https://www.niams.nih.gov/health-topics/psoriasis#:~:text=Psoriasis%20is%20a%20chronic%20(long,can%20be%20affected%20as%20well).

- NICE (National Institute for Health and Clinical Excellence). (2017). Psoriasis: assessment and management. Accessed Dec 2nd, 2023 from <https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf-35109629621701>
- Nick, D. A. N. D., Mahil, S. K., Capon, F., Smith, C. H., Simpson, M. A., & Barker, J. N. (2020). Psoriasis and genetics. *Acta dermato-venereologica*, 100(3).
- Novartis, P. (2018). Targeted therapies for psoriatic arthritis: an update for the dermatologist. In *Seminars in cutaneous medicine and surgery* (Vol. 37, pp. 173-181).
- Nyongombe, G., Kabongo, G. L., Noto, L. L., & Dhlamini, M. S. (2022). Advantage of Dimethyl Sulfoxide in the Fabrication of Binder-Free Layered Double Hydroxides Electrodes: Impacts of Physical Parameters on the Crystalline Domain and Electrochemical Performance. *International Journal of Molecular Sciences*, 23(17), 10192.
- Olivier, C., Robert, P. D., Daihung, D. O., Urba, G., Catalin, M. P., Hywel, W., ... & Gelfand, J. M. (2010). The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Archives of dermatology*, 146(8), 891-895.
- Papp, K. A., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K. B., ... & Efalizumab Study Group. (2006). Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. *International journal of dermatology*, 45(5), 605-614.
- Pariser, D., Schenkel, B., Carter, C., Farahi, K., Brown, T. M., Ellis, C. N., & Psoriasis Patient Interview Study Group. (2016). A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. *Journal of Dermatological Treatment*, 27(1), 19-26.
- Parisi, R., Iskandar, I. Y., Kontopantelis, E., Augustin, M., Griffiths, C. E., & Ashcroft, D. M. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *Bmj*, 369.
- Patel, U., Mark, N. M., Machler, B. C., & Levine, V. J. (2011). Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. *British Journal of Dermatology*, 164(3), 670-672.
- Patten, S. B., & Neutel, C. I. (2000). Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis and management. *Drug safety*, 22, 111-122.
- Peri, D., Meker, S., Manna, C. M., & Tshuva, E. Y. (2011). Different ortho and para electronic effects on hydrolysis and cytotoxicity of diamino bis (phenolato)"salan" Ti (IV) complexes. *Inorganic Chemistry*, 50(3), 1030-1038.
- Picardi, A., Lega, I., & Tarolla, E. (2013). Suicide risk in skin disorders. *Clinics in dermatology*, 31(1), 47-56.
- Pompili, M., Bonanni, L., Gualtieri, F., Trovini, G., Persechino, S., & Baldessarini, R. J. (2021). Suicidal risks with psoriasis and atopic dermatitis: Systematic review and meta-analysis. *Journal of psychosomatic research*, 141, 110347.
- Portugal-Cohen, M., Horev, L., Ruffer, C., Schlippe, G., Voss, W., Oron, M., ... & Kohen, R. (2012). Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. *Biomedicine & Pharmacotherapy*, 66(4), 293-299.

- Qi, F., Tan, Y., Yao, A., Yang, X., & He, Y. (2021). Psoriasis to Psoriatic Arthritis: The Application of Proteomics Technologies. *Frontiers in Medicine*, 8, 681172.
- Raharja, A., Mahil, S. K., & Barker, J. N. (2021). Psoriasis: a brief overview. *Clinical medicine (London, England)*, 21(3), 170–173. <https://doi.org/10.7861/clinmed.2021-0257>
- Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. *International journal of molecular sciences*, 20(6), 1475.
- Riss, T. L., Moravec, R. A., & Niles, A. L. (2013). Cell viability assays In: Sittampalam GS, Coussens NP, Brimacombe K. et al., eds. *Assay Guidance Manual*. Bethesda, MD, USA: Eli Lilly & Company and the National Center for Advancing Translational Sciences.
- Saleh, D., & Tanner, L. S. (2018). Guttate psoriasis.
- Sampogna, F., Tabolli, S., & Abeni, D. (2012). Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. *Acta dermato-venereologica*, 92(3), 299-303.
- Sathish, J. G., Sethu, S., Bielsky, M. C., De Haan, L., French, N. S., Govindappa, K., ... & Park, B. K. (2013). Challenges and approaches for the development of safer immunomodulatory biologics. *Nature reviews Drug discovery*, 12(4), 306-324.
- Segall, M. D., & Barber, C. (2014). Addressing toxicity risk when designing and selecting compounds in early drug discovery. *Drug discovery today*, 19(5), 688-693.
- Sharma, A., Upadhyay, D. K., Gupta, G. D., Narang, R. K., & Rai, V. K. (2022). IL-23/Th17 Axis: A potential therapeutic target of psoriasis. *Current Drug Research Reviews Formerly: Current Drug Abuse Reviews*, 14(1), 24-36.
- Shi, P., Jiang, Q., Zhao, Y., Zhang, Y., Lin, J., Lin, L., ... & Guo, Z. (2006). DNA binding properties of novel cytotoxic gold (III) complexes of terpyridine ligands: the impact of steric and electrostatic effects. *JBIC Journal of Biological Inorganic Chemistry*, 11, 745-752.
- Şikar Aktürk, A., Özdoğan, H. K., Bayramgürler, D. İ. L. E. K., Çekmen, M. B., Bilen, N., & Kıran, R. (2012). Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. *Journal of the European Academy of Dermatology and Venereology*, 26(7), 833-837.
- Singh, R. K., Lee, K. M., Ucmak, D., Brodsky, M., Atanelov, Z., Farahnik, B., ... & Liao, W. (2016). Erythrodermic psoriasis: pathophysiology and current treatment perspectives. *Psoriasis: Targets and Therapy*, 93-104.
- Sivamani, R. K., Goodarzi, H., Garcia, M. S., Raychaudhuri, S. P., Wehrli, L. N., Ono, Y., & Maverakis, E. (2013). Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. *Clinical reviews in allergy & immunology*, 44, 121-140.
- Snast, I., Reiter, O., Atzmony, L., Leshem, Y. A., Hodak, E., Mimouni, D., & Pavlovsky, L. (2018). Psychological stress and psoriasis: a systematic review and meta-analysis. *British Journal of Dermatology*, 178(5), 1044-1055.
- Son, S., Shin, E., & Kim, B. S. (2015). Redox-degradable biocompatible hyperbranched polyglycerols: synthesis, copolymerization kinetics, degradation, and biocompatibility. *Macromolecules*, 48(3), 600-609.

- Suárez-Farinas, M., Li, K., Fuentes-Duculan, J., Hayden, K., Brodmerkel, C., & Krueger, J. G. (2012). Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. *Journal of Investigative Dermatology*, 132(11), 2552-2564.
- Sun, J., Zhao, Y., & Hu, J. (2013). Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. *PLoS one*, 8(6), e67078.
- Takehita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017). Psoriasis and comorbid diseases: epidemiology. *Journal of the American Academy of Dermatology*, 76(3), 377-390.
- Tan, C. S., & Koralnik, I. J. (2010). Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. *The Lancet Neurology*, 9(4), 425-437.
- Tashiro, T., & Sawada, Y. (2022). Psoriasis and systemic inflammatory disorders. *International Journal of Molecular Sciences*, 23(8), 4457.
- Tedesco, S., De Majo, F., Kim, J., Trenti, A., Trevisi, L., Fadini, G. P., ... & Vitiello, L. (2018). Convenience versus biological significance: are PMA-differentiated THP-1 cells a reliable substitute for blood-derived macrophages when studying in vitro polarization?. *Frontiers in pharmacology*, 9, 71.
- Tseng, C. H., Lin, C. F., Aljuffali, I. A., Huang, J. R., Yang, S. H., & Fang, J. Y. (2022). The effectiveness of synthetic methoxylated isoflavones in delivering to the skin and alleviating psoriasisiform lesions via topical absorption. *International Journal of Pharmaceutics*, 617, 121629.
- Tseng, C. H., Lin, C. S., Shih, P. K., Tsao, L. T., Wang, J. P., Cheng, C. M., ... & Chen, Y. L. (2009). Furo [3', 2': 3, 4] naphtho [1, 2-d] imidazole derivatives as potential inhibitors of inflammatory factors in sepsis. *Bioorganic & medicinal chemistry*, 17(18), 6773-6779.
- Ueyama, A., Yamamoto, M., Tsujii, K., Furue, Y., Imura, C., Shichijo, M., & Yasui, K. (2014). Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. *The Journal of dermatology*, 41(2), 135-143.
- Vence MD, L., Schmitt, A., Meadows MD, C., & Gress MPH, T. W. (2015). Recognizing guttate psoriasis and initiating appropriate treatment.
- Villanova, F., Di Meglio, P., & Nestle, F. O. (2015). Targeted therapies and biomarkers for personalized treatment of psoriasis. *Personalized treatment options in dermatology*, 77-100.
- Warren, R. B., Weatherhead, S. C., Smith, C. H., Exton, L. S., Mohd Mustapa, M. F., Kirby, B., ... & Brain, A. G. (2016). British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. *British Journal of Dermatology*, 175(1), 23-44.
- WHO (World Health Organization). (2016). Psoriasis. <https://www.who.int/docs/default-source/ncds/psoriasis-info-sheet-3.pdf?sfvrsn=a5d14e81>
- Wilson, F. C., Icen, M., Crowson, C. S., McEvoy, M. T., Gabriel, S. E., & Kremers, H. M. (2009). Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. *Arthritis Care & Research*, 61(2), 233-239.
- Xu, C., Liu, S., Liu, Z., Song, F., & Liu, S. (2013). Superoxide generated by pyrogallol reduces highly water-soluble tetrazolium salt to produce a soluble formazan: A simple assay for measuring

superoxide anion radical scavenging activities of biological and abiological samples. *Analytica chimica acta*, 793, 53-60.

Zeng, C., Wang, W., Yu, X., Yang, L., Chen, S., & Li, Y. (2015). Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. *Science China Life Sciences*, 58, 1282-1287.

Zhang, M. Q., Chen, B., Zhang, J. P., Chen, N., Liu, C. Z., & Hu, C. Q. (2020). Liver toxicity of macrolide antibiotics in zebrafish. *Toxicology*, 441, 152501.